NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Gelteq Limited (GELS) Stock Analysis

Gelteq Limited (GELS) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GELS

$0.44

−$0.01 (−1.83%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GELS with… →

GELS Key Statistics

As of Oct 21, 2026

Trading

Open: $0.44
Previous Close: $0.45
Day's Range: 0.44–0.44
52-Week Range: 0.39–2.01
Volume: 7.25K

Valuation

Market Cap: $4.71M
P/E Ratio: unprofitable
P/S ratio: 9.98
EPS (ttm): −0.44

Financials (FY)

Revenue (FY): $165.65K
Net Income (FY): −$6.65M
Shares Outstanding: 10.71M
1-Year Return: −64.82%

Dividend and dates

Avg Volume: 2.86M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GELS closed at $0.44, −64.82% over 1 year.

Gelteq Limited (GELS) has a market capitalization of $4.71M.

In fiscal 2025, GELS reported revenue of $165.65K.

GELS Stock Return by Calendar Year

Gelteq Limited (GELS) return since Oct 2024: what $10,000 became

1 year: $10,000 $3,518; −64.82%
Since Oct 2024: $10,000 $1,496; −85.04%

If you had invested $10,000 in Gelteq Limited (GELS) at the close on October 29, 2024, the earliest close on record here, it would have been worth $1,496 at the close on October 21, 2026: −85.04% in total, −61.75% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−21.09%−65.52%−45.03%

2024*20252026*

Year	Return
2026 (partial year)	−45.03%
2025	−65.52%
2024 (partial year)	−21.09%

As of October 21, 2026.

GELS Revenue and Earnings by Fiscal Year

FY ends June

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$165.65K	−$6.65M	−4,011.9%
2024	$0.00	−$3.55M	—
2023	$79.84K	−$3.51M	−4,391.4%
2022	$147.54K	−$3.37M	−2,283.4%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$165.65K	—	−$4.95M	−$6.65M	−4,011.9%
2024	$0.00	$0.00	−$2.61M	−$3.55M	—
2023	$79.84K	$30.92K	−$3.38M	−$3.51M	−4,391.4%
2022	$147.54K	$52.66K	−$3.19M	−$3.37M	−2,283.4%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

GELS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks

Metric	GELS	Drug Manufacturers - Specialty & Generic median	vs median
P/S ratio	9.98	2.10	4.8x the median

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Gelteq Limited (GELS) carries a market capitalisation of $4.71M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 7.

The most recent close on file for GELS is $0.44, dated October 21, 2026. That is −$0.01 (−1.83%) against the previous close. The 52-week range on file runs from $0.39 to $2.01. The latest close sits 13.64% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $165.65K. The same year closed with a net loss of $6.65M. Earnings per share on a trailing basis come to −0.44.

Across the 4 fiscal years on file, revenue moves from $147.54K in 2022 to $165.65K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 9.98. On price-to-sales that is 4.8 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year total return is −64.82%. The stored price history starts on October 29, 2024, and the total return since then is −85.04%. Annualized volatility over the trailing 2 years is 267.76%.

Growth & Income

No dividend is on file for GELS.

The record holds one complete calendar year, 2025, which returned −65.52%. 2026 is still running; the total return is −45.03% year to date.

Peer Comparison

Gelteq Limited (GELS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Gelteq Limited	GELS	$4.71M	—
Takeda Pharmaceutical Company Limited	TAK	$63.67B	—
Teva Pharmaceutical Industries Limited	TEVA	$47.37B	67.7
Haleon plc	HLN	$44.06B	20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Gelteq Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

TEVA

Teva Pharmaceutical Industries Limited

$47.37B

HLN

Haleon plc

$44.06B

ZTS

Zoetis Inc.

$32.90B

UTHR

United Therapeutics Corporation

$24.17B

VTRS

Viatris Inc.

$21.19B

View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Gelteq Limited

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.

Visit website →